Koninklijke Philips (NYSE:PHG) Stake Lifted by Capital Analysts LLC

Capital Analysts LLC increased its stake in Koninklijke Philips (NYSE:PHG) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,820 shares of the technology company’s stock after acquiring an additional 521 shares during the period. Capital Analysts LLC’s holdings in Koninklijke Philips were worth $206,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PHG. Citigroup Inc. lifted its stake in Koninklijke Philips by 1.3% during the first quarter. Citigroup Inc. now owns 36,882 shares of the technology company’s stock valued at $1,126,000 after purchasing an additional 483 shares during the last quarter. Advisory Services Network LLC lifted its stake in Koninklijke Philips by 28.7% during the first quarter. Advisory Services Network LLC now owns 2,226 shares of the technology company’s stock valued at $41,000 after purchasing an additional 496 shares during the last quarter. 1832 Asset Management L.P. lifted its stake in Koninklijke Philips by 1.1% during the first quarter. 1832 Asset Management L.P. now owns 56,735 shares of the technology company’s stock valued at $1,708,000 after purchasing an additional 619 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in Koninklijke Philips by 3.2% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 22,616 shares of the technology company’s stock valued at $451,000 after purchasing an additional 696 shares during the last quarter. Finally, Holderness Investments Co. lifted its stake in Koninklijke Philips by 4.4% during the second quarter. Holderness Investments Co. now owns 16,507 shares of the technology company’s stock valued at $358,000 after purchasing an additional 697 shares during the last quarter. 13.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. StockNews.com raised shares of Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. BNP Paribas downgraded shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Koninklijke Philips Stock Performance

Shares of NYSE:PHG opened at $19.98 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.78 and a current ratio of 1.20. Koninklijke Philips has a 52 week low of $17.75 and a 52 week high of $24.27. The firm has a 50 day simple moving average of $20.39 and a 200 day simple moving average of $20.85.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings results on Monday, January 29th. The technology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.47 billion. Koninklijke Philips had a negative net margin of 2.53% and a positive return on equity of 14.17%. Research analysts forecast that Koninklijke Philips will post 1.53 EPS for the current fiscal year.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.